CAMBRIDGE, England--(BUSINESS WIRE)-- Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has contributed to two new peer-reviewed papers under the U.S. Food and Drug Administrations (FDA) CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative. The papers, in Nature Scientific Reports1 and Toxicology and Applied Pharmacology2, focus on application of improved cardiac safety testing protocols and recommendations for best practice for the drug discovery industry.
The CiPA Initiative (www.cipaproject.org), which began in July 2013 following a workshop at the US FDA, has the objective to revise and enhance the regulatory framework assessing cardiac safety of new chemical entities. Under current guidelines, new therapeutics undergo initial assessment of proarrhythmic risk by measuring activity against the hERG cardiac ion channel, before progressing to studies in preclinical animal models and ultimately, a Thorough QT interval study in the clinic. The CiPA initiative aims to extend the use of advances in early electrophysiology-based cardiac ion channel screening, in silico predictive modelling, and human induced pluripotent stem cell derived cardiomyocytes to improve the accuracy and reduce the cost of predicting the cardiac liability of new drug candidates. Metrions research forms part of the first stage of the proposed harmonisation work, to provide clarity on how to standardise cardiac ion channel assays to ensure they deliver consistent data for in silico models of clinical cardiac arrythmia risk.
The first paper1, published in Nature Scientific Reports on 27th March 2020 by an international group of authors drawn from 20 different commercial and academic laboratories, including Metrion Biosciences, was coordinated by the Health and Environmental Sciences Institute (HESI). It reviews data from a multi-year, multi-site collaboration across industry, academia and the FDA regulatory agency to optimize experimental protocols and reduce experimental variability and bias. The goal of the study was to guide the development of best practices for the use of automated patch clamp technologies in early cardiac safety screening. High quality in vitro cardiac ion channel data is required for accurate and reliable characterisation of the risk of delayed repolarisation and proarrhythmia in the human heart and to guide subsequent clinical studies and regulatory submissions.
The second paper2, to be published formally in Toxicology and Applied Pharmacology paper on 1st May 2020 but currently available online, uses automated patch clamp data from the CiPA consortium to address the lack of statistical quantification of variability, which hinders the use of primary hERG potency data to predict cardiac arrhythmia. The consortium establishes a more systematic approach to estimate hERG block potency and safety margins.
Dr Marc Rogers, CSO, Metrion Biosciences, said: The Metrion team has been a participant in the international CiPA Initiative since inception and we are now pleased to be able to announce the publication of our data from this global collaborative scientific effort. We believe these projects will make a significant contribution to the eventual revision of cardiac safety testing guidelines by the FDA and other international regulatory agencies. They also contribute to deepening our knowledge of the underlying causes of proarrhythmia, which will help prevent early attrition of potentially promising drugs.
Contributing organisations to the Nature Scientific Reports CiPA study include: Charles River Laboratories; Bayer AG; Sophion Bioscience A/S; Nanion Technologies; GlaxoSmithKline PLC; Pfizer; Sanofi R&D; Astra Zeneca; BSYS GmbH; Bristol-Myers Squibb Company; Eurofins Discovery; Merck; Metrion Biosciences Ltd.; Natural and Medical Science Institute at the University of Tbingen; Northwestern Feinberg School of Medicine, Chicago; Roche Innovation Center Basel; Novoheart; Health and Environmental Sciences Institute, Washington, DC; AbbVie.
Contributing organisations to the Toxicology and Applied Pharmacology hERG study include: Center for Drug Evaluation and Research, Food and Drug Administration; Eli Lilly and Company; AstraZeneca; CiPA LAB; NMI-TT GmbH; Sophion Bioscience A/S; B'SYS GmbH; The Ion Channel Company; F. Hoffmann-La Roche AG; Eurofins Discovery; Bristol-Myers Squibb; Merck & Co., Inc; Metrion Biosciences Ltd.; Nanion Technologies; Charles River Laboratories; Bayer AG; University of Nottingham; Universit de Lille.
For more information on Metrions fully integrated Cardiac Safety Screening / CiPA Screening service, please visit: https://www.metrionbiosciences.com/services/cardiac-safety-screening/
Merion Biosciences comprehensive cardiac safety testing White Paper The changing landscape of cardiac safety will also be available on the Companys website from 13th April 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005408/en/
Read more here:
- High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma - News-Medical.Net - December 11th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of - GlobeNewswire - December 11th, 2024
- Stem Cell Therapy Market to Worth Over US$ 2,612.92 Million By 2033 | Astute Analytica - GlobeNewswire - December 11th, 2024
- Changes in Blood Cell Production Over the Lifetime | Newswise - Newswise - December 7th, 2024
- Study reveals how stem cells respond to environmental signals, with implications for IBD and colorectal cancer - Medical Xpress - December 5th, 2024
- Stem cell therapy TED-A9 showing safety and early efficacy in trial - Parkinson's News Today - December 5th, 2024
- BMP-2 loaded scaffold for stem and immune cell recruitment in therapeutic applications - News-Medical.Net - December 5th, 2024
- Stem Cell Treatment May Help To Cure Vision Loss - Anti Aging News - December 5th, 2024
- BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024... - December 3rd, 2024
- Stem Cell Therapy Strategic Business Report 2024 - - GlobeNewswire - December 3rd, 2024
- Enhancing the efficacy of cell transplantation therapy for stroke or traumatic brain injury - Medical Xpress - December 1st, 2024
- Apheresis in Cellular Therapies: Unlocking Quality for CAR T and Stem Cell Treatments, Upcoming Webinar Hosted by Xtalks - PR Web - November 29th, 2024
- Stem Cell Therapy Market is expected to Double Its Size by Upcoming Decade - openPR - November 29th, 2024
- AmeraCell Revolutionizes Regenerative Medicine with Accessible and Affordable Stem Cell Clinics - openPR - November 29th, 2024
- Making fat cells skinny: Findings could lead to new, more effective therapies for managing diabetes - Medical Xpress - November 25th, 2024
- Designer Cells Could Be the Key to Autoimmune Disease Treatment - VICE - November 25th, 2024
- Why do athletes store their body cells? - The Times of India - November 22nd, 2024
- What Stem Cell Treatments Canand CantDo - Men's Health - November 22nd, 2024
- Can Regenerative Medicine Speed Up Sports Injury Recovery? Expert Weighs In - Onlymyhealth - November 22nd, 2024
- How Stem Cell Therapy Works for Knee Osteoarthritis: A Cutting-Edge Treatment Explained - Salon Priv Magazine - November 22nd, 2024
- Genting breaks ground on stem cell facility in Bali, Indonesia - theSun - November 22nd, 2024
- A New Stem Cell Therapy for Parkinson's Disease Has Been Confirmed Safe and Effective for the First Time - AccessWire - November 20th, 2024
- More stem cells for sickle cell gene therapy readied with motixafortide - Sickle Cell Disease News - November 20th, 2024
- Isolation and identification of patient-derived liver cancer stem cells and development of personalized treatment strategies - Journal of... - November 20th, 2024
- Stem Cell Therapy Market Expected To Reach 31.33 Billion, - GlobeNewswire - November 18th, 2024
- A look at the broad range of therapies offered sponsored by NeoGenix Stem Cell and Regenerative Therapies - WCNC.com - November 18th, 2024
- Worlds first stem-cell treatment restores vision for patients with severe corneal damage - The Times of India - November 18th, 2024
- MEDEZE Group Wins Industry Champions of the Year at ACES Award, Leads Stem Cell Innovation - Bangkok Post - November 18th, 2024
- Human vision restored by stem cell replacement in regenerative medicine breakthrough - Medical Xpress - November 12th, 2024
- Stem cells grown in space show super powers but theres a catch - Study Finds - November 12th, 2024
- Developing the Cell-Based Therapies of the Future - University of Miami - November 12th, 2024
- Japan performs world's first stem cell-treatment to restore vision - DrugsControl.org - November 12th, 2024
- HRT, Stem Cells, & Nitric Oxide: What This Longevity Expert Wants You To Know - mindbodygreen - November 10th, 2024
- Stem Cell Market Potential: Revolutionizing Regenerative Medicine and Therapeutics - openPR - November 10th, 2024
- Whats coming up at Cell & Gene Therapy International Europe 2024? - RegMedNet - November 10th, 2024
- The Team Stem Cell Medicine Ltd. - November 8th, 2024
- Stem Cell Medicine (SCM) Receives Israeli Government Funding for Gene ... - November 8th, 2024
- About Us Stem Cell Medicine Ltd. - November 8th, 2024
- Stem cell therapy improves mental, physical health in relapsing-remitting MS - Healio - November 8th, 2024
- Stem cells can tailor their role in gene therapy based on the underlying disease, study suggests - Medical Xpress - November 8th, 2024
- Researchers are one step closer to developing cell-based therapy for hypothyroidism - Medical Xpress - November 8th, 2024
- Sickle cell patient dies in Beam study of base editing therapy - BioPharma Dive - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - GlobeNewswire - November 8th, 2024
- Asymmetrex Presents the Impact of Differential Stem Cell Counting for Cultured Meat Production - EIN News - October 30th, 2024
- Minor cannabinoid shows promise in reducing anxiety - Drug Discovery News - October 30th, 2024
- Experts call for clear and concise regulation of exosome-based treatments - Medical Xpress - October 27th, 2024
- Stem cells: Arthritic vulture reunited with partner after jab - BBC.com - October 25th, 2024
- Cholesterol medications might be able to be repurposed for MS: Study - Multiple Sclerosis News Today - October 25th, 2024
- Cell and Gene Therapies Symposium Open to Public | Newswise - Newswise - October 25th, 2024
- Could This Protein Hold the Key to Reversing Brain Aging and Repairing Damage? - SciTechDaily - October 24th, 2024
- Arthritic vulture Bernard has his knee fixed in stem cell first - BBC.com - October 24th, 2024
- Findings in fruit flies could lead to new Parkinsons stem cell therapies - Parkinson's News Today - October 24th, 2024
- Stem Cell Therapy Market Size to Hit USD 48.89 Billion by 2033 - GlobeNewswire - October 22nd, 2024
- Japan mulls ways to boost cell, gene therapy approvals - BioWorld Online - October 22nd, 2024
- Meso Numismatics Changes Name to Regenerative Medical Technology Group and Ticker Symbol to RMTG - Newswire - October 22nd, 2024
- Medeze Group Awarded Frost & Sullivan's 2024 Southeast Asia Company of the Year for Delivering Highly Innovative Stem Cell and Longevity Solutions... - October 20th, 2024
- MexStemCells Clinic Partners with PlacidWay Medical Tourism to Expand Global Access to Regenerative Medicine - EIN News - October 20th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - The Conversation - October 18th, 2024
- Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology,... - October 18th, 2024
- Healing begins with research: Promising development program on stem cells in rare diseases - Pharmaceutical Technology - October 15th, 2024
- Chuck Murry | Stem cell science for healing the heart - University of Southern California - October 15th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Medical Xpress - October 15th, 2024
- AI Scaling Laws Poised To Transform Cell Replacement Therapy - Forbes - October 15th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 15th, 2024
- Stem cell discovery highlights importance of DNA methylation in cancer - Medical Xpress - October 11th, 2024
- $8.1M Grant Will Allow Researchers to Study the Ro | Newswise - Newswise - October 11th, 2024
- Crackdowns on Unproven Stem Cell Therapies Worked Abroad - Medpage Today - October 10th, 2024
- Improving Access to Cell and Gene Therapy in Pedia | Newswise - Newswise - October 10th, 2024
- Osteopore Partners with RxCell for Regenerative Medicine - TipRanks - October 10th, 2024
- USC's Keck School of Medicine partners with StemCardia to advance heart failure treatment - News-Medical.Net - October 10th, 2024
- Dr. Abdul Baker Pioneers Robotic Surgery and Stem Cell Therapy for Innovative Treatment & Recovery - openPR - October 8th, 2024
- How a Court Ruling Affects California Stem Cell Clinics That Use Unproven Therapies - KQED - October 8th, 2024
- Stem-cell therapy reverses type 1 diabetes in groundbreaking case study - Medical News Today - October 4th, 2024
- Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in... - October 4th, 2024
- Stem cell therapy to cure T1 diabetes? The Indian perspective - The Hindu - October 4th, 2024
- Stem cell therapy for osteoarthritis: Functional cartilage regeneration using 3d bioprinting technology - Open Access Government - October 4th, 2024
- Innovative Opportunities in Stem Cell Treatments: Insights from Genoma - Medical Tourism Magazine - October 4th, 2024
- BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - Yahoo Finance - October 4th, 2024
- Palmetto Stem Cell Therapy Advises on Streamlining the Regenerative Medicine Process for Joint Pain Relief - The Globe and Mail - October 2nd, 2024
- Woman's Own Stem Cells Appear to Reverse Her Type 1 Diabetes in First-Ever Procedure - Futurism - October 2nd, 2024
Recent Comments